The Intensive Care Medicine research agenda on critically ill oncology and hematology patients

TY - JOUR

T1 - The Intensive Care Medicine research agenda on critically ill oncology and hematology patients

AU - Azoulay, Elie

AU - Schellongowski, Peter

AU - Darmon, Michael

AU - Bauer, Philippe R

AU - Benoit, Dominique

AU - Depuydt, Pieter

AU - Divatia, Jigeeshu V

AU - Lemiale, Virginie

AU - van Vliet, Maarten

AU - Meert, Anne-Pascale

AU - Mokart, Djamel

AU - Pastores, Stephen M

AU - Perner, Anders

AU - Pène, Frédéric

AU - Pickkers, Peter

AU - Puxty, Kathryn A

AU - Vincent, Francois

AU - Salluh, Jorge

AU - Soubani, Ayman O

AU - Antonelli, Massimo

AU - Staudinger, Thomas

AU - von Bergwelt-Baildon, Michael

AU - Soares, Marcio

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Over the coming years, accelerating progress against cancer will be associated with an increased number of patients who require life-sustaining therapies for infectious or toxic chemotherapy-related events. Major changes include increased number of cancer patients admitted to the ICU with full-code status or for time-limited trials, increased survival and quality of life in ICU survivors, changing prognostic factors, early ICU admission for optimal monitoring, and use of noninvasive diagnostic and therapeutic strategies. In this review, experts in the management of critically ill cancer patients highlight recent changes in the use and the results of intensive care in patients with malignancies. They seek to put forward a standard of care for the management of these patients and highlight important updates that are required to care for them. The research agenda they suggest includes important studies to be conducted in the next few years to increase our understanding of organ dysfunction in this population and to improve our ability to appropriately use life-saving therapies or select new therapeutic approaches that are likely to improve outcomes. This review aims to provide more guidance for the daily management of patients with cancer, in whom outcomes are constantly improving, as is our global ability to fight against what is becoming the leading cause of mortality in industrialized and non-industrialized countries.

AB - Over the coming years, accelerating progress against cancer will be associated with an increased number of patients who require life-sustaining therapies for infectious or toxic chemotherapy-related events. Major changes include increased number of cancer patients admitted to the ICU with full-code status or for time-limited trials, increased survival and quality of life in ICU survivors, changing prognostic factors, early ICU admission for optimal monitoring, and use of noninvasive diagnostic and therapeutic strategies. In this review, experts in the management of critically ill cancer patients highlight recent changes in the use and the results of intensive care in patients with malignancies. They seek to put forward a standard of care for the management of these patients and highlight important updates that are required to care for them. The research agenda they suggest includes important studies to be conducted in the next few years to increase our understanding of organ dysfunction in this population and to improve our ability to appropriately use life-saving therapies or select new therapeutic approaches that are likely to improve outcomes. This review aims to provide more guidance for the daily management of patients with cancer, in whom outcomes are constantly improving, as is our global ability to fight against what is becoming the leading cause of mortality in industrialized and non-industrialized countries.

KW - Journal Article

KW - Review

U2 - 10.1007/s00134-017-4884-z

DO - 10.1007/s00134-017-4884-z

M3 - Review

C2 - 28725926

SN - 0935-1701

VL - 43

SP - 1366

EP - 1382

JO - European Journal of Intensive Care Medicine

JF - European Journal of Intensive Care Medicine

IS - 9

ER -